HBV相关中和抗体在慢性乙型肝炎抗病毒治疗中的研究进展  

Progress of hepatitis B virus-associated neutralizing antibody in antiviral therapy of chronic hepatitis B

作　　者：赵宇迪 黄明星[1] Zhao Yudi;Huang Mingxing(Center for Infectious Disease Control,the Fifth Affiliated Hospital of Sun Yat-sen University,Zhuhai 519000,China)

机构地区：[1]中山大学附属第五医院感染病防治中心,珠海519000

出　　处：《新医学》2022年第11期802-805,共4页Journal of New Medicine

摘　　要：HBV感染不仅是一项重要的全球性公共卫生问题,也是我国正在面临的一项重要挑战。虽然现在已有针对HBV的疫苗并且其接种普及率也在逐年提高,但仍然有很多的乙型肝炎患者亟待治疗。中和抗体作为HIV一项重要的治疗方法同样在HBV的治疗研究领域被寄予厚望。目前针对HBV相关中和抗体的研究主要包括G12、Bc1.187、H017、H019、BX-182、KR127和2H5-A14,其中H017和H019联合应用以及2H5-A14在动物实验中在免疫耐受性和中和活性研究中均取得相当不错的进展。该文就HBV相关中和抗体的研究进展进行综述,以探究其未来可能的发展方向及应用前景。Chronic hepatitis B virus infection is not only an important global public health problem but also an important challenge in our country.Although there are some vaccines for hepatitis B and its prevalence is increasing year by year,there are still many patients in need of treatment.Neutralizing antibody as an important treatment for HIV is also promising in the field of hepatitis B cure.Current studies on neutralizing antibodies related to hepatitis B virus mainly include G12,Bc1.187,H017,H019,BX-182,KR127 and 2H5-A14,among which H017 and H019 combined application and 2H5-A14 have achieved quite good results in immune tolerance and neutralization activity in animal experiments.This article reviews the research progress of neutralizing antibodies related to hepatitis B virus to explore the possible development direction and application prospect in the future.

关 键 词：乙型肝炎 中和抗体 功能性治愈 乙型肝炎病毒表面抗原 乙型肝炎病毒表面抗体 

分 类 号：R512.62[医药卫生—内科学]